Log In | Register FREE | Schedule a DEMO | Solution Enquiry | Subscribe
X

Shukra Pharmaceuticals Ltd Stock Analysis

Small Cap
Evaluated by 34 users | BSE: 524632 | NSE: |
Pharmaceuticals & Drugs
10YEAR X-RAY

10 Year X-Ray

Standalone basis Standalone basis P Consolidated basis

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 14.86%-6.57%-9.09%-6.25%-1.05%3.43%3.52%3.35%2.31%-0.15%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 9.96.65.14.42.64.85.15.35.711.9
Y-o-Y Gr. Rt.--32.8%-22.9%-13.3%-41.8%87.2%6.4%3.9%6%109.4%
Adjusted EPS (Rs.) 0.59-0.5-0.85-4.82-0.993.23.23.372.95-0.23
Y-o-Y Gr. Rt.--184.8%NANANANA0%5.3%-12.5%-107.8%
Book Value per Share (Rs.) 0.581.64-0.4288.2989.1389.8993.195.8698.298.43
Adjusted Net Profit 0.7-0.6-1-0.8-0.20.50.50.50.50
Net Op. Cash Flow (Rs. Cr.) 1.6-7.110.4-3.1-22.7-0.30.80.31.2
Debt to Cash Flow from Ops 3.19-1.470.97-0.1-0.590.01-0.124.2823.386.49
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Shukra Pharmaceuticals Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 2.1%35.7%32.1%109.4%
Adjusted EPS -190.1%NA-141.6%-107.8%
Book Value per Share 76.921.90.2
Share Price 47.9% 6.3% -7.5% 156.8%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 392.22-59.68-193.34-11.26-1.123.573.53.573.04-0.23
Operating Profit Margin (%) 11.264.3310.09-2.11-9.5824.5428.5130.2329.1413
Net Profit Margin (%) 7.12-8.96-19.71-17.01-6.0310.389.759.888.16-0.3
Debt to Equity 10.077.12-23.490.020.09000.240.390.52
Working Capital Days 277612601390879392379467526334
Cash Conversion Cycle 74161179901657564314039
shareholding patterns

Shareholding Pattern

Entity Percentage Holding
Promoters 49.17%
Institutions 0.80%
Non-Institutions 50.04%
shareholding patterns

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
shareholding patterns

FAQs

1. Is Shukra Pharmaceuticals Ltd a good quality company?
Data is not available for this company.
2. Is current market price of Shukra Pharmaceuticals Ltd a good price to buy it?

The 5-year analysis of Shukra Pharmaceuticals Ltd's performance infers:

Shukra Pharmaceuticals Ltd earnings have grown by 0%, whereas share price has appreciated 6.3% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

3. What is Shukra Pharmaceuticals Ltd share price return in the past 10 years ?

Data is not available for this company

shareholding patterns

About Company

No data to display
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback